Suggested remit: To appraise the clinical and cost effectiveness of remdesivir within its marketing authorisation for treating coronavirus disease 2019 (COVID-19) in people with pneumonia requiring supplemental oxygen.
 
Status Proposed
Process STA 2018

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
06 October 2020 (10:00) Scoping workshop
18 August 2020 - 16 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance